What's happened
A series of stories from The Guardian and New York Post highlight a subset of patients who do not respond to GLP-1 and related obesity drugs. Reports describe high costs, treatment failures, and potential risks, including eating-disorder concerns and ADHD diagnoses among adults.
What's behind the headline?
Contextual framing
- The Guardian piece centers on individuals for whom GLP-1s do not work despite high expectations.
- The New York Post reports on cases of eating disorders and ADHD diagnoses surfacing among adults seeking GLP-1 therapies.
- Both pieces discuss screening gaps and patient experiences, highlighting variability in outcomes.
What this implies
- The drugs are not a universal solution; tailoring requires understanding patient-specific factors.
- Safety and mental-health considerations require robust pre-screening and monitoring.
Questions readers should ask
- How common are non-responders, and what predicts non-response?
- Are there standardized screening protocols for eating disorders before GLP-1 prescriptions?
- How are clinicians preventing misuse and ensuring patient safety with dosing?
How we got here
GLP-1 class drugs (e.g., Ozempic, Wegovy) and tirzepatide-based therapies (e.g., Mounjaro, Zepbound) have generated widespread attention for weight loss. Trials show average substantial weight loss, but a minority fail to respond. Reports also raise issues of screening for eating disorders before prescriptions and off-label dosing practices.
Our analysis
The Guardian reports on Mercedes and broader GLP-1 efficacy; New York Post articles discuss eating disorders risk, screening gaps, and ADHD diagnoses related to GLP-1 use.
Go deeper
- What is the scale of non-response to GLP-1 drugs across different studies?
- Should clinics implement mandatory eating-disorder screening before GLP-1 prescriptions?
- What safeguards exist to prevent misuse or dangerous dose escalations?